CPX-351

Phase 1 Dose Escalation Study of CPX-351 for Patients With Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia After Failure to Hypomethylating Agents

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
38 patients (estimated)
Sponsors
MD Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
Tags
Chemotherapy
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
1528
NCT Identifier
NCT03896269

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.